{"id":53955,"date":"2026-01-13T21:16:54","date_gmt":"2026-01-13T13:16:54","guid":{"rendered":"https:\/\/flcube.com\/?p=53955"},"modified":"2026-01-13T21:16:55","modified_gmt":"2026-01-13T13:16:55","slug":"merck-and-abbiskos-pimicotinib-nda-accepted-by-fda-for-tgct-building-on-china-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53955","title":{"rendered":"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval"},"content":{"rendered":"\n<p><strong>Merck KGaA<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:ETR\">ETR: MRK<\/a>) and <strong>Abbisko Therapeutics Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2256:HKG\">HKG:\u202f2256<\/a>) announced that the <strong>U.S. FDA<\/strong> has accepted the <strong>New Drug Application (NDA)<\/strong> for <strong>pimicotinib (ABSK021)<\/strong>, an oral, highly selective CSF\u20111R inhibitor for the systemic treatment of <strong>tenosynovial giant cell tumor (TGCT)<\/strong>, with a <strong>PDUFA target date<\/strong> in <strong>Q3\u202f2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Applicants<\/strong><\/td><td>Merck (worldwide commercialization) \/ Abbisko (originator)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Pimicotinib (ABSK021)<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>NDA (New Drug Application)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>US FDA<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Symptomatic TGCT where surgery risks functional limitation or severe morbidity<\/td><\/tr><tr><td><strong>Filing Date<\/strong><\/td><td>13\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>PDUFA Target<\/strong><\/td><td>Q3\u202f2026<\/td><\/tr><tr><td><strong>China Approval<\/strong><\/td><td>NMPA approved (Dec\u202f2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Potent, selective <strong>colony\u2011stimulating factor 1 receptor (CSF\u20111R) inhibitor<\/strong> blocking CSF\u20111\/IL\u201134 signaling, reducing tumor\u2011associated macrophages and TGCT synovial proliferation<\/li>\n\n\n\n<li><strong>Administration:<\/strong> <strong>Once\u2011daily oral tablet<\/strong>, offering convenience vs. intra\u2011articular injections or surgery<\/li>\n\n\n\n<li><strong>Global Rights:<\/strong> Abbisko licensed worldwide commercialization rights to <strong>Merck<\/strong> in 2021; Abbisko retains co\u2011promotion rights in Greater China<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First <strong>oral, systemic therapy<\/strong> targeting the underlying disease driver of TGCT; surgery remains the current standard but causes high morbidity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-phase-iii-maneuver-trial\">Clinical Evidence \u2013 Phase\u202fIII MANEUVER Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Pimicotinib (n\u202f=\u202f86)<\/th><th>Placebo (n\u202f=\u202f87)<\/th><th>Treatment Difference<\/th><th>p\u2011Value<\/th><\/tr><\/thead><tbody><tr><td><strong>ORR at Week\u202f25 (primary)<\/strong><\/td><td><strong>68.6\u202f%<\/strong><\/td><td>12.6\u202f%<\/td><td>+56.0\u202fppt<\/td><td>&lt;\u202f0.0001<\/td><\/tr><tr><td><strong>Active Range of Motion (\u0394 degrees)<\/strong><\/td><td>+28.5<\/td><td>+3.2<\/td><td>+25.3<\/td><td>&lt;\u202f0.0001<\/td><\/tr><tr><td><strong>Physical Function Score (\u0394)<\/strong><\/td><td>+18.4<\/td><td>+2.1<\/td><td>+16.3<\/td><td>&lt;\u202f0.0001<\/td><\/tr><tr><td><strong>Stiffness Reduction (VAS, \u0394 mm)<\/strong><\/td><td>\u201132.1<\/td><td>\u20115.8<\/td><td>\u201126.3<\/td><td>&lt;\u202f0.0001<\/td><\/tr><tr><td><strong>Pain Reduction (\u0394)<\/strong><\/td><td>\u201129.8<\/td><td>\u20114.5<\/td><td>\u201125.3<\/td><td>&lt;\u202f0.0001<\/td><\/tr><tr><td><strong>Grade\u202f\u2265\u202f3 TEAEs<\/strong><\/td><td>22\u202f% (AST\/ALT elevation)<\/td><td>8\u202f%<\/td><td>\u2013<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>MANEUVER met all primary and secondary endpoints with <strong>robust tumor shrinkage<\/strong> and <strong>meaningful symptom improvement<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-competitive-landscape\">Market Impact &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>US TGCT Incidence<\/strong><\/td><td>8,500<\/td><td>8,700<\/td><td>8,900<\/td><\/tr><tr><td><strong>Surgery\u2011Eligible Refractory Cases<\/strong><\/td><td>3,400<\/td><td>3,480<\/td><td>3,560<\/td><\/tr><tr><td><strong>Pimicotinib Market Share<\/strong><\/td><td>0\u202f%<\/td><td>25\u202f%<\/td><td>42\u202f%<\/td><\/tr><tr><td><strong>Annual Treatment Cost (USD)<\/strong><\/td><td>\u2013<\/td><td>$125,000<\/td><td>$118,000<\/td><\/tr><tr><td><strong>Merck US Revenue Forecast<\/strong><\/td><td>\u2013<\/td><td>$106\u202fmillion<\/td><td>$177\u202fmillion<\/td><\/tr><tr><td><strong>Abbisko China Revenue<\/strong><\/td><td>$45\u202fmillion<\/td><td>$62\u202fmillion<\/td><td>$78\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Standard:<\/strong> Surgical synovectomy (65\u202f% recurrence rate); no approved systemic therapy in US\/EU<\/li>\n\n\n\n<li><strong>Pipeline Competition:<\/strong><\/li>\n\n\n\n<li><strong>Daiichi Sankyo<\/strong> (pexidartinib \u2013 CSF\u20111R inhibitor) withdrawn due to hepatotoxicity<\/li>\n\n\n\n<li><strong>Deciphera<\/strong> (vimseltinib \u2013 CSF\u20111R inhibitor) Phase\u202fIII ongoing; PDUFA <strong>Q4\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Pimicotinib\u2019s <strong>cleaner liver safety profile<\/strong> (reversible AST\/ALT elevation) vs. competitors\u2019 black\u2011box warnings<\/li>\n\n\n\n<li><strong>Launch Readiness:<\/strong> Merck\u2019s US oncology sales force (800 reps) to target <strong>2,500 orthopedic oncologists<\/strong>; market access team preparing for <strong>payer coverage<\/strong> in Q1\u202f2027<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding FDA review timelines, commercial forecasts, and market penetration for pimicotinib. Actual results may differ due to regulatory outcomes, competitive dynamics, and market access negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG:\u202f2256) announced that the U.S. FDA&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[186,16,1147,921,38,120,33],"class_list":["post-53955","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-abbisko-therapeutics","tag-cancer","tag-etr-mrk","tag-hkg-2256","tag-market-approval-filings","tag-merck","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG:\u202f2256) announced that the U.S. FDA has accepted the New Drug Application (NDA) for pimicotinib (ABSK021), an oral, highly selective CSF\u20111R inhibitor for the systemic treatment of tenosynovial giant cell tumor (TGCT), with a PDUFA target date in Q3\u202f2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53955\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval\" \/>\n<meta property=\"og:description\" content=\"Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG:\u202f2256) announced that the U.S. FDA has accepted the New Drug Application (NDA) for pimicotinib (ABSK021), an oral, highly selective CSF\u20111R inhibitor for the systemic treatment of tenosynovial giant cell tumor (TGCT), with a PDUFA target date in Q3\u202f2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53955\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T13:16:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T13:16:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53955#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53955\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval\",\"datePublished\":\"2026-01-13T13:16:54+00:00\",\"dateModified\":\"2026-01-13T13:16:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53955\"},\"wordCount\":393,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Abbisko Therapeutics\",\"Cancer\",\"ETR: MRK\",\"HKG: 2256\",\"Market approval filings\",\"Merck\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53955#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53955\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53955\",\"name\":\"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-13T13:16:54+00:00\",\"dateModified\":\"2026-01-13T13:16:55+00:00\",\"description\":\"Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG:\u202f2256) announced that the U.S. FDA has accepted the New Drug Application (NDA) for pimicotinib (ABSK021), an oral, highly selective CSF\u20111R inhibitor for the systemic treatment of tenosynovial giant cell tumor (TGCT), with a PDUFA target date in Q3\u202f2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53955#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53955\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53955#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval - Insight, China&#039;s Pharmaceutical Industry","description":"Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG:\u202f2256) announced that the U.S. FDA has accepted the New Drug Application (NDA) for pimicotinib (ABSK021), an oral, highly selective CSF\u20111R inhibitor for the systemic treatment of tenosynovial giant cell tumor (TGCT), with a PDUFA target date in Q3\u202f2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53955","og_locale":"en_US","og_type":"article","og_title":"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval","og_description":"Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG:\u202f2256) announced that the U.S. FDA has accepted the New Drug Application (NDA) for pimicotinib (ABSK021), an oral, highly selective CSF\u20111R inhibitor for the systemic treatment of tenosynovial giant cell tumor (TGCT), with a PDUFA target date in Q3\u202f2026.","og_url":"https:\/\/flcube.com\/?p=53955","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T13:16:54+00:00","article_modified_time":"2026-01-13T13:16:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53955#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53955"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval","datePublished":"2026-01-13T13:16:54+00:00","dateModified":"2026-01-13T13:16:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53955"},"wordCount":393,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Abbisko Therapeutics","Cancer","ETR: MRK","HKG: 2256","Market approval filings","Merck","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53955#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53955","url":"https:\/\/flcube.com\/?p=53955","name":"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-13T13:16:54+00:00","dateModified":"2026-01-13T13:16:55+00:00","description":"Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG:\u202f2256) announced that the U.S. FDA has accepted the New Drug Application (NDA) for pimicotinib (ABSK021), an oral, highly selective CSF\u20111R inhibitor for the systemic treatment of tenosynovial giant cell tumor (TGCT), with a PDUFA target date in Q3\u202f2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53955#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53955"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53955#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck and Abbisko\u2019s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53955"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53955\/revisions"}],"predecessor-version":[{"id":53957,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53955\/revisions\/53957"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}